SureTrader
Home > Boards > US Listed > Medical - Drugs >

Precipio Inc. (PRPO)

PRPO RSS Feed
Add PRPO Price Alert      Hide Sticky   Hide Intro
Moderator: beambe
Search This Board: 
Last Post: 4/20/2018 9:43:30 PM - Followers: 70 - Board type: Free - Posts Today: 1


Home

Link to coporate website:
http://www.transgenomic.com/

TICKER SYMBOL:TBIO
Share Structure
Market Value1 $40,142,705 a/o May 10, 2013
Shares Outstanding 88,225,725 a/o Mar 13, 2013
Float Not Available
Authorized Shares 100,000,000 a/o Aug 02, 2011
Par Value 0.01

TRANSFER AGENT:
Wells Fargo Bank Minnesota, N.A.
Shareowner Services
P.O. Box 64854
St. Paul, MN 55164-0854
Phone: 877-602-7611

About:
Transgenomic is a global biotechnology company that provides unique products and services for automated high sensitivity genetic variation and mutation analysis. Our offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of pharmacogenomics and personalized medicine.

Transgenomic offers its WAVE® DHPLC Systems and associated consumables. These systems are specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification and have broad applicability to genetic research. To date there have been over 1600 systems shipped to more than 30 countries.

Transgenomic's SURVEYOR® Mutation Detection Kits and the SURVEYOR Check-It Kit provide reagents and protocols for the detection of mutations in DNA.

Transgenomic's Cytogenetics offering includes HANABI automated chromosome harvesting systems that improve laboratory productivity with consistent quality compared to manual methods.

Transgenomic Clinical Reference Laboratory provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases.

Transgenomic Genomic Research Services is a CRO for pharmacogenomic, translational research and clinical trials.



Colorectal Cancer Testing



Very important AMGEN signs collaberation deal with Mgmt:

"Another potential meaningful near-term contributor to the Lab Services segment (as well as to the Diagnostic Tools segment) relates to the recently consummated agreement with Amgen (NasdaqGS:AMGN) whereby the two companies are collaborating on a KRAS an NRAS gene mutation assay kit to screen patients for colorectal cancer.  The RAScan test is currently available for research use only (RUO) in the U.S. (which will run through Lab Svcs) and for clinical use in Europe - which could help accelerate instrument placements (through Menarini) as well as increase consumables sales"



CRC RAScan™ is a new mutation detection test designed to screen for selected KRAS and NRAS mutations (collectively referred to as “RAS mutations”), in patients with metastatic colorectal cancer (mCRC).The identification of these RAS mutations can give physicians important clinical information to help them make better treatment decisions for their mCRC patients.

KRAS and NRAS are part of the RAS family of genes which encode proteins involved in transmitting signals within cells. When Ras proteins are “switched on” by incoming signals, other genes involved in cell growth, differentiation, and survival are activated. Mutations in KRAS, NRAS and other related genes can lead to Ras proteins becoming permanently activated, causing overactive signaling even in the absence of incoming signals, and can lead to the uncontrolled cell growth that characterizes cancer. Mutations that permanently activate Ras proteins are found in ~25% of human tumors and up to 90% of certain cancers. About 40% of colorectal tumors carry KRAS gene mutations and these mutations have been associated with poor response to EGFR antagonists such as cetuximab and panitumumab. Therefore KRAS mutation status can be used to determine whether or not a patient with colorectal cancer will respond to anti-EGFR therapy.

The CRC RAScan test can identify mCRC patients who have RAS mutations at levels that cannot be detected using traditional Sanger Sequencing methods.

CRC RAScan™ for Colorectal Cancer Tumor Testing is available immediately from Transgenomic’s CLIA-certified laboratory in the United States. For more information on this test, click here.

CRC RAScan Mutation Detection Kits will soon be available in the U.S for research use only. CRC RAScan Mutation Detection Kits include the following kits based on Transgenomic's proprietary SURVEYOR® Nuclease technology:

  • KRAS Exon 2
  • KRAS Exons 3 & 4
  • NRAS Exons 2, 3 & 4

Zacks analyst ~ OUR 2013 OUTLOOK~

We've again made some updates to our model.  We now model 2013 revenue of $32.4 million, implying growth of 3% from 2012.  We look for Laboratory Services and Instruments to generate revenue of $20.0 million (+4%) and $12.4 million (+2%), respectively.  We think net income and EPS come in at ($12.7) million and ($0.14).


2013 ASCO CONFERENCE ABSTRACT

http://www.amgen.com/media/media_pr_detail.jsp?year=2013&releaseID=1820728




May. 15, 2013 AMGEN PRESS RELEASE
New Analyses Identify Predictive Biomarkers For Vectibix® (Panitumumab) In Patients With Metastatic Colorectal Cancer

Biomarker Analysis From Phase 3 PRIME ('203) Study and Phase 2 PEAK ('509) Study Link Additional RAS Gene Mutations to Vectibix Clinical Response

THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from three analyses of Vectibix® (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as a first-line treatment for metastatic colorectal cancer (mCRC). These analyses include the description of new predictive biomarkers of clinical response to Vectibix, activating mutations in KRAS (beyond exon 2) and mutations in NRAS, collectively referred to as RAS.

"Amgen helped establish KRAS gene mutation as a biomarker for lack of response to anti-EGFR treatment," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "The identification of new biomarkers may further help to identify appropriate patients with this incurable disease for such treatment."

 









Contact Information:
Phone: (402) 452-5437
E-mail: investorrelations@transgenomic.com

SEC Filings:
http://www.nasdaq.com/asp/quotes_sec.asp?page=filings&symbol=TBIO&selected=TBIO&rpage=sec&


Press Releases:
http://finance.yahoo.com/q?s=TBIO.OB








   
SureTrader
PRPO
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#1794   its testing me my name is 04/20/18 09:43:30 PM
#1793   Guess they gonna prop the price up before stock1ace1 04/18/18 08:42:43 AM
#1792   Prpo @.54 P/m News stock1ace1 04/18/18 08:38:08 AM
#1791   $PRPO NEW PRODUCT "Juno" will disrupt gynecology gopherdat 04/13/18 10:43:30 PM
#1790   PRPO files 10-K aries4747 04/13/18 05:10:07 PM
#1789   i continue to like what I see come PennyStockTrader2 04/13/18 02:45:34 PM
#1788   between 2,38 / 4.47 is a huge down pietro13 04/12/18 05:40:19 AM
#1787   Acne affects at least 85% of the population at gopherdat 04/11/18 08:55:29 PM
#1786   wouldn’t mind a gap and run tomorrow my name is 04/11/18 05:58:01 PM
#1785   who cares! you will either lose some or my name is 04/08/18 03:38:48 PM
#1784   Its a penny stock and yes it is carldfw 04/08/18 10:47:48 AM
#1783   This is Nasdaq. IPO$ 04/08/18 10:27:59 AM
#1782   I dont know It poped up on a carldfw 04/08/18 09:41:11 AM
#1781   The cancer kit doesn’t work? IPO$ 04/08/18 09:23:37 AM
#1780   Just wait for the home lobotomy kit carldfw 04/08/18 09:11:27 AM
#1779   Cancer kits IPO$ 04/08/18 08:31:26 AM
#1778   Board moderator is too busy with tops and carldfw 04/07/18 10:46:35 PM
#1777   COMPANY NOTES carldfw 04/07/18 09:38:49 PM
#1776   This is a NASDAQ stock which is reputable IPO$ 04/07/18 05:46:24 PM
#1775   I am not sure but most of these Hot trader101 04/07/18 05:45:55 PM
#1774   Why isn’t there website working? This is a IPO$ 04/07/18 05:43:31 PM
#1773   I’ve been following for a while and after Hot trader101 04/07/18 05:42:32 PM
#1772   Why? IPO$ 04/07/18 04:38:40 PM
#1771   Great stock to buy big gains coming! Hot trader101 04/06/18 10:47:27 AM
#1770   Thinking you caught close to bottom, mgland. aries4747 04/06/18 10:29:18 AM
#1769   lookin’ good my name is 04/05/18 08:13:53 PM
#1768   what a steal my name is 04/04/18 07:05:38 PM
#1767   Back in this @ $.429 mgland 04/04/18 01:32:08 PM
#1766   I hope its not like biel heb sanp carldfw 04/02/18 11:57:15 PM
#1765   yep it did carldfw 04/02/18 11:25:10 PM
#1764   this thing could go stupid my name is 03/29/18 09:58:10 AM
#1763   Haha maybe QuidRunner 03/28/18 12:54:29 PM
#1762   Are they diluting via atm? akamaii 03/28/18 11:52:23 AM
#1761   Yeah, hopefully this selling with stop soon and QuidRunner 03/28/18 11:03:10 AM
#1760   Was doing so well in pre-market.... bcapps66 03/28/18 10:46:20 AM
#1759   Easy non-invasive cancer detection means. This will QuidRunner 03/28/18 10:14:22 AM
#1758   Vermillion(VRMLQ had a similar test approved by the PeteBonk 03/28/18 08:27:34 AM
#1757   Nope no money in 3rd world country's. What carldfw 03/27/18 11:37:38 AM
#1756   profit? who cares. chart looks tastey! my name is 03/27/18 10:00:26 AM
#1755   anybody think this will ever become a profitable company profittrader00 03/26/18 10:28:25 AM
#1754   Looking good pre market T695 03/26/18 08:16:46 AM
#1753   this is about the uglieat weakly chart i've my name is 03/23/18 11:31:41 AM
#1752   i like it my name is 03/22/18 08:19:55 PM
#1751   This was very very interesting. Luckily I was PennyStockTrader2 03/22/18 07:49:54 PM
#1750   good NEWS beambe 03/22/18 08:56:31 AM
#1749   Maybe .46 is buying level lol T695 03/21/18 02:40:39 PM
#1748   Looks like it was pump and dump imo Roadtojourney 03/21/18 02:20:55 PM
#1747   WOW boy was I wrong yaboy520 03/21/18 02:01:34 PM
#1746   The more i buy the more it goes Roadtojourney 03/21/18 11:34:25 AM
#1745   my .62 filled wow that was quick perhaps my name is 03/21/18 11:03:11 AM
PostSubject